

## **CARL BJARTMAR APPOINTED CHIEF COMMERCIAL OFFICER OF ICOAT MEDICAL**

**Lund, Sweden, 5 April 2023.**

iCoat Medical, “iCoat” a pioneer in drug development to attenuate ischemia reperfusion injury, announces today that Carl Bjartmar, MD, PhD, will join the company as Chief Commercial Officer. Carl Bjartmar currently serves on the Board of Directors of iCoat Medical and will maintain this position as well while joining the organization as Chief Commercial Officer on a consultancy basis. He will report to CEO Peder Waern and join the Executive Committee.

Peder Waern, CEO says, “iCoat Medical is rapidly evolving into an internationally active, clinical-stage pharmaceutical company and the time is right to start developing our commercial and in-market leadership as we grow into a high-performing commercial organization. We are excited to welcome Carl to iCoat Medical, and this underscores our commitment to bringing onboard high caliber talents. Carl has a long and solid track record in late-stage orphan drug development and has among other things been a key member of the Wilson Therapeutics management team with important achievements including an IPO on Nasdaq OMX in 2016, planning and execution of phase 3 development and the acquisition of Wilson Therapeutics by Alexion Pharmaceuticals in 2018. Recently, Carl served as the CMO of Ascelia Pharma where he contributed to their IPO on Nasdaq OMX in 2019 and subsequently led their global late-stage clinical development.

With over 20 years of international experience in the pharmaceutical industry, Carl Bjartmar brings substantial experience in late-stage drug development and commercial preparations in rare diseases having served in senior roles in both large international pharma companies such as Sanofi, Genzyme and Lundbeck as well as in the Swedish biotech company Wilson Therapeutics as CMO. Carl is a Medical Doctor (M.D.) and holds a PhD degree from University of Linköping.

Carl Bjartmar says: “I could not be more excited to join iCoat Medical – with a promising coating technology platform, impressive scientific and clinical talent, and an opportunity to help people with medical conditions affected by ischemia reperfusion injuries, this is a company that is poised to achieve great things. I’m looking forward to partnering across the enterprise to build out the organization and initiate the global commercial priorities.”

For more information, please contact:  
Peder Waern, CEO – iCoat Medical AB  
E-mail: [peder.waern@icoatmedical.com](mailto:peder.waern@icoatmedical.com)

**Bifogade filer**

---

**[Carl Bjartmar appointed Chief Commercial Officer of iCoat Medical](#)**